Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42308548.
- Also identified by DOI 10.1093/jnci/djag196.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pivotal phase III trials underpin regulatory approval of immunotherapy (IO) and BRAF/MEK inhibitors (BRAF/MEKi) in metastatic melanoma (MM). However, how trial-derived efficacy benchmarks translate into real-world effectiveness across eligibility strata remains insufficiently quantified. We conducted a nationwide registry-based cohort study using the Danish Metastatic Melanoma Database, including patients with stage IV MM treated in first line with anti-PD-1 monotherapy, anti-PD-1/anti-CTLA-4, or BRAF/MEKi between 2014 and 2023. Real-world outcomes were compared with reconstructed pseudo-individual patient data from pivotal trials as regulatory efficacy benchmarks. Trial eligibility was defined using key exclusion criteria from pivotal studies. Overall survival (OS), progression-free survival (PFS), and melanoma-specific survival (MSS) were analyzed using Kaplan-Meier and Cox regression methods. Among 1909 patients, 41.7-44.9% of IO-treated and 74.3% of BRAF/MEKi-treated patients were trial-ineligible. In eligible populations, IO outcomes mirrored regulatory benchmarks. In contrast, trial-ineligible patients experienced substantial effectiveness deviations, with significantly higher mortality hazards for anti-PD-1 monotherapy (OS HR 1.61, 95% CI 1.39-1.86; p < 0.001) and nivolumab/ipilimumab (OS HR 1.30, 95% CI 1.02-1.66; p = 0.035) compared to their reference trials. For BRAF/MEKi, real-world outcomes were inferior to regulatory benchmarks even among trial-eligible patients and were markedly worse in trial-ineligible populations, with hazard ratios >2.5 across OS, MSS, and PFS (all p < 0.001). Real-world effectiveness of first-line therapies in MM deviates from regulatory trial benchmarks in trial-ineligible populations, with larger discrepancies for BRAF/MEKi than IO. These findings support population-specific effectiveness evaluation to complement trial-based efficacy estimates and inform health-technology assessment and clinical decision-making.